bluuebunny/crossref_metadata_2025_split huggingface dataset:
Update on the Use of Platelet-Rich Plasma Injections in the Management of Musculoskeletal Injuries: A Systematic Review of Studies From 2014 to 2021
Authors: O’Dowd Aidan 
Published: December 2022

Background: There has been expanding use of platelet-rich plasma (PRP) in the management of musculoskeletal soft tissue injuries. Purpose: To determine if there are any recent studies that show any clear benefits regarding the use of PRP in the management of soft tissue injuries. Study Design: Systematic review. Methods: This review was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The EMBASE, MEDLINE, PubMed, and Cochrane Bone, Joint and Muscle Group Specialised Register databases were queried for randomized controlled trials comparing PRP with a non-PRP/placebo in participants >18 years of age with musculoskeletal soft tissue injuries. Exclusion criteria were non–soft tissue injuries and research published in journals with an impact factor <3.5. The main outcome measure analyzed across all injury types was the effect of PRP injections on pain and function. Results: Of the 853 studies initially screened, 32 were included in this review. There were 13 studies that investigated the effects of PRP on the management of rotator cuff injuries; 7 studies that investigated PRP in conjunction with arthroscopy found no significant difference between PRP groups and controls, while 5 of 6 studies that investigated nonsurgical management showed positive results for PRP. Eight studies investigated various tendinopathies; of these, 2 studies demonstrated positive results for PRP in Achilles and gluteal tendinopathy management. Six studies examined PRP in acute soft tissue injuries, with 2 of these reporting significant improvements in recovery time for hamstring injuries and 1 study showing positive results for ankle ligament injuries. Two studies looked at acute rupture of soft tissues and found no benefit to PRP use. Two studies investigated PRP injections for chronic plantar fasciitis, and both reported positive results in pain and function with PRP. Finally, 1 study evaluated the effects of PRP on meniscal injuries and reported significant improvement in the healing rate and a decreased need for surgical repair. Conclusion: Currently, there is no research strongly advocating the use of PRP compared with traditional management strategies (rest, ice, corticosteroid injection, rehabilitation program). No long-term physiological benefits were reported to justify the invasive and costly technique of obtaining, producing, and implementing PRP.
Knowledge and Perceptions of Ulnar Collateral Ligament Injuries in Baseball Players: A Survey of NCAA Head Baseball Coaches
Authors: Beaudry Mason F. , Beaudry Anna G. , Benzinger Brett C. , Gilliam Bradley D. , Haynes David E. 
Published: December 2022

Background: There is growing concern among sports medicine professionals regarding the increasing prevalence of ulnar collateral ligament (UCL) surgery in baseball players. At this time, it is unclear whether collegiate head baseball coaches possess adequate knowledge of UCL injuries. Purpose/Hypothesis: The purpose of this study was to assess the knowledge and perceptions of UCL injury among National Collegiate Athletic Association (NCAA) head baseball coaches. It was hypothesized that NCAA head baseball coaches would demonstrate misconceptions and knowledge disparities regarding UCL injury. Study Design: Cross-sectional study. Methods: An online 35-question survey was designed to assess NCAA head baseball coaches’ knowledge of UCL injury. The survey included questions related to participant characteristics, UCL injury, biometric performance and pitching variables, throwing fatigue, surgical variables/performance outcomes, and collegiate athlete recruitment. A total of 788 NCAA head baseball coaches were asked to participate. Responses were analyzed and reported using descriptive statistics where appropriate. Statistical comparisons and contrasts were made using chi-square and Fisher exact tests. Results: A total of 103 NCAA head baseball coaches participated in the survey, representing a 13.1% response rate. Only 31% of respondents could correctly identify all UCL injury symptoms, and 93% recommended <8 weeks off from overhead throwing during the off-season. Previous elbow injury observation was associated with UCL symptom identification (χ2 = 10.614; P = .005). Regular access to an athletic trainer ( P = .015) and regular access to a strength and conditioning coach ( P = .004) were both associated with NCAA division status, with Division I programs having the most access. Neither sports medicine physician ( P = .656) nor athletic trainer ( P = .611) access was associated with the geographic location of the baseball program; however, strength and conditioning coach access was associated with geographic location (χ2 = 6.696; P = .010). Conclusion: This study demonstrates that limited UCL injury knowledge and various misconceptions exist among NCAA baseball head coaches. The majority of responding coaches recommended an amount of time off from overhead throwing during the off-season that may be inadequate and were unable to identify all symptoms associated with UCL injury, representing the most concerning findings of the present study.
Simple and efficient: performance of palladium-loaded sepiolite for electrocatalytic ethanol oxidation
Authors: Zhao Junkai , Li Liang , Li Liuqiang , Zhang Siru , Chen Shiqi , Yuan Zheng , Wang Ling 
Published: December 2022

AbstractHigh-performance electrodes with outstanding catalysts play a vital role in the commercial application of direct ethanol fuel cells. In the present study, a supported catalyst with controllable Pd loading, prepared using a facile impregnation method with sepiolite as a carrier, was synthesized and tested for electrocatalytic oxidation of ethanol. Physical characterization revealed the pore structure and large specific surface area of the sepiolite, which provided excellent conditions for the loading of nanometal clusters. The Pd-sepiolite had greater electrocatalytic ethanol activity and anti-intermediate product poisoning performance than a metallic Pd disc electrode under alkaline conditions. Under these experimental conditions, the electrochemical activity in terms of ethanol oxidation increased significantly with increasing Pd loading. Considering both the activity and stability of the electrodes, 23 wt.% Pd loading on sepiolite was selected with a coating amount of 140 μg cm–2 on glassy carbon. Factors such as ethanol/potassium hydroxide concentration, scanning rate and temperature had direct impacts on peak current densities as well as on reaction kinetics as depicted by Tafel plots. The electrochemical impedance test showed that Pd intercalation could improve significantly the conductivity of sepiolite and reduce the electron-transfer resistance in the electrocatalytic process. Thus, Pd-loaded sepiolite is a simple and effective catalyst for direct ethanol fuel cells.
Adsorption of lead by kaolinite, montmorillonite, goethite and ferrihydrite: performance and mechanisms based on quantitative analysis
Authors: Mao Xiao , Liu Haibo , Chu Ziyang , Chen Tianhu , Zou Xuehua , Chen Dong , Zhang Xuemei , Hu Jinchao 
Published: December 2022

AbstractThis work elucidated the performance and mechanisms of Pb2+ adsorption by kaolinite, montmorillonite, goethite and ferrihydrite using batch experiments. The contributions of various adsorption mechanisms were quantified using a stepwise extraction method. Several characterizations (scanning electron microscopy, X-ray diffraction, Fourier-transform infrared spectroscopy, point of zero charge analysis and X-ray fluorescence) were utilized to analyse the physicochemical properties and the potential adsorption mechanisms. The results indicated that the adsorption processes of montmorillonite and goethite approached equilibrium within 20 min, while 60 min were required for the adsorption processes of kaolinite and ferrihydrite. The adsorption processes of Pb2+ by the four minerals best fit the pseudo-second order model. The adsorption capacities of the four minerals for Pb2+ followed the order: montmorillonite > goethite > ferrihydrite > kaolinite, and the maximum adsorption capacities were 69.20, 46.95, 34.32 and 18.62 mg g–1, respectively. The stepwise extraction test showed that the adsorption mechanism of Pb2+ was dominated by ion exchange for montmorillonite, precipitation and complexation for goethite and complexation for kaolinite and ferrihydrite.
Bounahasite, Cu+Cu2+2(OH)3Cl2, a new mineral from the Bou Nahas Mine, Morocco
Authors: Lykova Inna , Rowe Ralph , Poirier Glenn , Friis Henrik , Helwig Kate 
Published: December 2022

AbstractThe new mineral bounahasite, Cu+Cu2+2(OH)3Cl2, was found in the oxidation zone of the Bou Nahas Mine, Morocco. It forms pseudo-hexagonal plates up to 3 × 30 × 40 μm in size combined in loose clusters with native copper and paratacamite. The mineral is green with vitreous lustre. The cleavage is parallel to {110}, perfect. Dcalc is 3.90 g/cm3. The infrared spectrum is reported. The composition (wt.%) is Cu2O 23.26, CuO 51.72, Cl 23.36, H2O 8.71, O = Cl2 –5.27, total 101.78. The empirical formula calculated on the basis of 3 Cu atoms per formula unit is: Cu+Cu2+2(OH)2.97Cl2.03. The mineral is monoclinic, P21/n, a = 8.5925(1), b = 6.4189(1), c = 10.4118(2) Å, β = 111.804(2)°, V = 533.17(2) Å3 and Z = 4. The strongest reflections of the powder X-ray diffraction pattern [d,Å(I)(hkl)] are: 7.71(70)($\bar{1}$01), 5.34(22)(011), 3.856(100)(012, $\bar{2}$02), 2.673(36)(022), 2.665 (30)(103) and 2.350 (71)($\bar{1}$23, 301, $\bar{2}$14). The crystal structure, refined from single-crystal X-ray diffraction data (R1 = 0.028), is based on two alternating sheets coplanar to (110): one consists of alternating edge-sharing Cu2+(OH)6 octahedra and two Cu2+(OH)4Cl2 octahedra, whereas the other one is based on Cu+Cl4 tetrahedra forming edge-sharing Cu+2Cl6 dimers.
A comparison of the fenites at the Chilwa Island and Kangankunde carbonatite complexes, Malawi
Authors: Dowman Emma , Wall Frances , Treloar Peter 
Published: December 2022

AbstractCarbonatites are igneous carbonate rocks. They are the main source of the rare earth elements (REE) that are essential in low carbon and high technology applications. Exploration targeting and mine planning would both benefit from a better understanding of the processes that create the almost ubiquitous alkaline and REE-bearing metasomatic aureoles in the surrounding country rocks.Using scanning electron microscopy and whole-rock geochemistry, we investigated the composition and mineralogy of the fenite aureoles developed around the REE-poor Chilwa Island carbonatite and the REE-rich Kangankunde carbonatite, which intrude similar country rocks in the Chilwa Alkaline Province of Southern Malawi. Although common characteristics and trends in their mineralogy and composition may be typical of fenites in general, there are significant differences in their petrography and petrogenesis. For example, the mineralogically diverse breccia at Kangankunde contrasts with the intensely altered potassic breccia of Chilwa Island. This might be caused by differing sequences of fluids expelled from the carbonatites into the aureoles. The main REE-bearing mineral in fenite is different at each complex, and reflects the characteristic REE-bearing mineral of the main carbonatite: fluorapatite at Chilwa Island; and monazite at Kangankunde. Each fenite has distinctive mineral assemblages, in which the relative abundance of the REE-bearing minerals appears to be determined by the mineralogy of their respective host carbonatites.At both localities, the REE minerals in fenite are less enriched in lanthanum and cerium than their equivalents in carbonatite, a characteristic that we attribute to REE fractionation within fluids in the aureole.Identifying the mineral assemblages present in fenite and understanding the sequence of alkaline and mineralising fluid events could therefore be useful in predicting whether a fenite is associated with a REE-rich carbonatite. Detailed studies of other aureoles would be required to assess the reliability of these characteristics.
Hematology 2022—what is complete HLA match in 2022?
Authors: Spellman Stephen R. 
Published: December 2022

Abstract
Allogeneic hematopoietic cell transplantation (alloHCT) often represents the only curative treatment for various malignant and nonmalignant disorders. Initially, the only suitable donors were considered human leukocyte antigen (HLA)–matched or partially matched relatives. The founding of international unrelated donor and umbilical cord blood registries expanded unrelated donor options and access for patients. In the absence of a matched sibling donor (MSD) with 13% to 51% availability, the current consensus recommends use of a matched unrelated donor (MUD) at HLA-A, B, C, and DRB1 with consideration of matching at HLA-DPB1 and -DQB1. MUD donor availability (donor willing and available to donate) ranges from 29% to 78% with African American patients on the lower end and white non-Hispanic patients with the highest likelihood of a match. Recent studies comparing donor to no-donor treatment options in malignant disease consistently point to substantially better outcomes following alloHCT. In the absence of an MSD or MUD, alternative donor choices turn to haploidentical related (Haplo), mismatched unrelated donor (MMUD), and umbilical cord blood (UCB). Novel strategies for alloHCT, including the use of posttransplant cyclophosphamide-based graft vs host disease prophylaxis, have expanded the safety and effectiveness of transplant procedures across HLA barriers using Haplo and MMUD. The less restrictive matching requirements for UCB transplant are well documented and allow for transplant across multiply mismatched HLA alleles. When all donor options are considered, nearly all patients have an available donor. Here we discuss the likelihood of donor availability, complete HLA match by available donor type, and current controversies warranting future research.
In 2022, which is preferred: haploidentical or cord transplant?
Authors: Nagler Arnon , Mohty Mohamad 
Published: December 2022

Abstract
Allogeneic hematopoietic stem cell transplantation is the treatment of choice for high-risk hematological malignancies such as acute myeloid and lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Alternative donor transplantation from either haploidentical (haplo-SCT) or cord blood donor (CBT) is an established therapeutic alternative for patients who need transplants but lack a human leukocyte antigen–matched donor. Although haplo-SCT (mainly non–T-cell-depleted haplo-SCT with posttransplant cyclophosphamide) is increasing while CBT is decreasing worldwide (Figure 1), recent developments in CBT, especially cord blood expansion and other strategies to improve engraftment and immune reconstitution post-CBT, make CBT still a valuable option. This article discusses the 2 options based on the currently available data, focusing on adults, and tries to give some clues to help the transplant physician choose a haploidentical vs a cord blood donor. Given the limited numbers of published or ongoing well-designed randomized controlled trials comparing haplo-SCT to CBT and the overall similar clinical results in the available, mostly registry-based, and single-center studies, with substantial heterogeneity and variability, the decision to perform haplo-SCT or CBT in a given patient depends not only on the patient, disease, and donor characteristics and donor availability (although most if not all patients should have in principle an alternative donor) but also on the transplant physician's discretion and, most importantly, the center's experience and preference and ongoing protocols and strategies.
Management of TKI-resistant chronic phase CML
Authors: Hughes Timothy P. , Shanmuganathan Naranie 
Published: December 2022

Abstract
Chronic phase CML (CP-CML) patients who are resistant to 2 or more tyrosine kinase inhibitors (TKIs) have limited therapeutic options and are at significant risk for progression to the blast phase. Ponatinib has been the drug of choice in this setting for the past decade, but when given at full dose (45 mg/d), the risk of serious vascular occlusive events is substantial. Lower doses mitigate this risk but also reduce the efficacy. Emerging data suggest that a high dose of ponatinib is important to achieve response, but a lower dose is usually sufficient to maintain response, introducing a safer therapeutic pathway for many patients. The recent development and approval of the novel allosteric ABL1 inhibitor, asciminib, for CP-CML patients with resistant disease provides another potentially safe and effective option in this setting. These recent therapeutic advances mean that for most resistant CP-CML patients who have failed 2 or more TKIs, 2 excellent options are available for consideration—dose modified ponatinib and asciminib. Patients harboring the T315I mutation are also candidates for either ponatinib or asciminib, but in this setting, higher doses are critical to success. Lacking randomized comparisons of ponatinib and asciminib, the best choice for each clinical circumstance is often difficult to determine. Here we review emerging evidence from recent trials and make some tentative suggestions about which drug is preferable and at what dose in different clinical settings using case studies to illustrate the key issues to consider.
CNS prophylaxis in aggressive B-cell lymphoma
Authors: Wilson Matthew R. , Bobillo Sabela , Cwynarski Kate 
Published: December 2022

Abstract
The prevention of central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) continues to be one of the most contentious areas of lymphoma management. Outcomes for patients with secondary CNS lymphoma (SCNSL) have historically been very poor. However, in recent years improved responses have been reported with intensive immunochemotherapy approaches, and there is a growing interest in potential novel/cellular therapies. Traditional methods for selecting patients for CNS prophylaxis, including the CNS International Prognostic Index, are hampered by a lack of specificity, and there is accumulating evidence to question the efficacy of widely employed prophylactic interventions, including intrathecal and high-dose methotrexate (HD-MTX). Given the potential toxicity of HD-MTX in particular and the ongoing need to prioritize systemic disease control in high-risk patients, there is an urgent need to develop more robust methods for identifying patients at highest risk of CNS relapse, as well as investigating prophylactic interventions with greater efficacy. Here we review new evidence in this field from the last 5 years, focusing on the potential use of molecular diagnostics to improve the identification of high-risk patients, recent large data sets questioning the efficacy of HD-MTX, and the current approach to management of patients with SCNSL. We provide a suggested algorithm for approaching this very challenging clinical scenario.
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity
Authors: Bottinor Wendy , Chow Eric J. 
Published: December 2022

Abstract
Five-year survival for childhood cancer now exceeds 85%. However, for many patients, treatment requires the use of intensive anthracycline-based chemotherapy and radiotherapy, both of which are associated with significant long-term cardiovascular toxicity. As such, late cardiovascular disease is now one of the leading causes of premature morbidity and mortality among childhood cancer survivors. Recent advances over the past decade have refined the cardiotoxic potential of various chemotherapeutics, and ongoing work seeks to determine the efficacy of various cardioprotective strategies in children receiving active cancer therapy. The development of risk prediction models offers an additional strategy to define risk for both newly treated and long-term survivors. Current screening strategies are primarily based on echocardiography, although there is active research investigating methods to further optimize screening through myocardial strain, cardiac magnetic resonance imaging, blood biomarkers, and genetics, along with the cost-effectiveness of different screening strategies. Active research is also underway investigating the efficacy of prevention strategies for childhood cancer survivors who have completed cancer therapy. This ranges from the use of medications to mitigate potential pathologic ventricular remodeling to reducing adverse and modifiable cardiovascular risk factors (eg, hypertension, dyslipidemia, insulin resistance, physical inactivity, tobacco exposure), many of which may be more common in cancer survivors vs the general population and are often underrecognized and undertreated in relatively young adult-aged survivors of childhood cancer.
Clinical screening for Ph-like ALL and the developing role of TKIs
Authors: Tran Thai Hoa , Tasian Sarah K. 
Published: December 2022

Abstract
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a common subtype of B-lineage acute lymphoblastic leukemia (B-ALL) with increasing frequency across the age spectrum. Characterized by a kinase-activated gene expression profile and driven by a variety of genetic alterations involving cytokine receptors and kinases, Ph-like ALL is associated with high rates of residual disease and relapse in patients treated with conventional chemotherapy. In this case-based review, we describe the biology of the 2 major ABL-class and JAK pathway genetic subtypes of Ph-like ALL, discuss current diagnostic testing methodologies, and highlight targeted inhibitor and chemo/immunotherapy approaches under clinical investigation in children, adolescents, and adults with these high-risk leukemias.
Biology of follicular lymphoma: insights and windows of clinical opportunity
Authors: Perrett Megan , Edmondson Carina , Okosun Jessica 
Published: December 2022

Abstract
Follicular lymphoma (FL) is a heterogeneous disease, both clinically and biologically. The biological behavior and development of FL is a culmination of complex multistep processes underpinned by genetic and nongenetic determinants. Epigenetic deregulation through recurrent genetic alterations is now a recognized major biological hallmark of FL, alongside the t(14;18) translocation. In parallel, there is a strong interplay between the lymphoma B cells and the immune microenvironment, with the microenvironment serving as a critical enabler by creating a tumor-supportive niche and modulating the immune response to favor survival of the malignant B cells. A further layer of complexity arises from the biological heterogeneity that occurs between patients and within an individual, both over the course of the disease and at different sites of disease involvement. Altogether, taking the first steps to bridge the understanding of these various biological components and how to evaluate these clinically may aid and inform future strategies, including logical therapeutic interventions, risk stratification, therapy selection, and disease monitoring.
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms
Authors: Akin Cem 
Published: December 2022

Abstract
Mast cell disorders include mastocytosis and mast cell activation syndromes. Mastocytosis is a rare clonal disorder of the mast cell, driven by KIT D816V mutation in most cases. Mastocytosis is diagnosed and classified according to World Health Organization criteria. Mast cell activation syndromes encompass a diverse group of disorders and may have clonal or nonclonal etiologies. Hematologists may be consulted to assist in the diagnostic workup and/or management of mast cell disorders. A consult to the hematologist for mast cell disorders may provoke anxiety due to the rare nature of these diseases and the management of nonhematologic mast cell activation symptoms. This article presents recommendations on how to approach the diagnosis and management of patients referred for common clinical scenarios.